Day: March 30, 2022

Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced the appointment of Professor Avi Schroeder as a member of the Company’s Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company’s top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroeder will advise the Company on the formulation development of SCI-160 to enhance the proprietary synthetic CB2 receptor...

TORONTO, March 30, 2022 (GLOBE NEWSWIRE) — Quisitive Technology Solutions, Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX:QUISF), a premier Microsoft solutions and payment solutions provider, today announced that it has officially received Mastercard certification to process credit and debit payments through its LedgerPay platform. Quisitive has successfully completed the certification process for its LedgerPay direct payment processing platform on the Mastercard network. After finalizing the configuration and installation of Mastercard’s hardware in mid-February and conducting joint certification tests, Quisitive is now fully approved to process transactions through Mastercard. Following the successful closing of the Company’s United States bank sponsorship with The Bancorp, and the recent Canadian bank sponsorship with...

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announces it has selected the corporate communications expertise of IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities. Silo is committed to developing innovative solutions to address conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. The company works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and...

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire — SPYR Inc. (OTCQB: SPYR) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Smarter Homes, Smarter Cars, Smarter People,” please visit: https://nnw.fm/H6egy  The Internet of Things (IoT) has evolved over the last couple decades, weaving its way into daily life by providing increased utility and functionality for everyday items. Broadly speaking, IoT refers to the overarching technology that connects physical items (e.g., refrigerators, door locks, HVAC) to the internet so they can be controlled from a mobile or desktop app to provide real-time...

Transformative Shockwave C2 Intravascular Lithotripsy Catheter Will Soon Be Available in One of the World’s Largest Coronary Intervention Markets SANTA CLARA, Calif., March 30, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Shockwave C2 Coronary IVL Catheter received the regulatory approval in Japan. “Coronary IVL has clearly demonstrated the ability to safely and effectively treat severely calcified coronary lesions in a Japanese population,” said Shigeru Saito, MD, FACC, FSCAI, FJCC, Director of the Department of Cardiology and Catheterization Laboratory at the Shonan Kamakura General Hospital in Kamakura, Japan and principal investigator of Disrupt CAD IV, one of the studies...

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) —  CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022. Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.Date:  Thursday, March 31, 2022Time:  5:30 am PT / 8:30...

Fully Executed Agreements establish new hub for cannabis delivery in Hollywood Hills as well as partnership in popular restaurant trend as exclusive provider for on-site cannabis event space NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Sugarmade, Inc. (OTC Pink: SGMD) (“Sugarmade”, “SGMD” or the “Company”) an emerging leader in the licensed cannabis sector, is pleased to announce the signing of Definitive Agreements (the “Agreements”) related to the Company’s expansion, including the establishment of majority ownership in a fully licensed new Hollywood cannabis delivery hub (the “Delivery Hub”) located on the world famous Sunset Strip as well as a minority stake in an expanding reservation-only restaurant brand with an adjacent private event space which will include cannabis...

Las Vegas, NV., March 30, 2022 (GLOBE NEWSWIRE) — China Dongsheng International Inc., (OTC Markets: CDSG) (the “Company” or “CDSG”) is currently reviewing and analyzing all geological data on its West End Lithium (“WEL”) project. The WEL project, next to the TLC Project being developed by American Lithium Corp. (LI.V), (OTCQB: LIACF), appears to be underlain by the same rock sequences. CDSG is planning a program of geological mapping, sampling, geochemical analysis, and drilling. The West End Lithium Project is located next to the same lithium mineralization hosted within the Miocene claystones of the Tonopah Lithium Claims (“TLC”) property held by American Lithium Corp. The TLC Project is a NI 43-101 compliant resource of 5.37 million tonnes of Lithium Carbonate Equivalent (“LCE”) in the Measured and Indicated category, which...

Substantially All Employees to Achieve Equity Ownership in Company ST. LOUIS, March 30, 2022 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today announced that it will give equity grants to approximately half of its employees, as part of an objective to ultimately make all Stifel employees shareholders. Through the program, approximately 4,200 current employees will receive a one-time restricted stock unit grant of $5,000 per individual. Going forward, qualifying new employees will be eligible for a similar award. With the implementation of this program, in combination with existing employee ownership, substantially all Stifel employees will achieve equity ownership in the company. Chairman and CEO Ronald Kruszewski commented, “At Stifel, we believe fostering an ownership mindset has been an essential part of our more than...

Results anticipated in H2 2022 NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the enrollment of the first patient in its Phase 2a randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy, safety, and pharmacokinetics (PK) of ACER-801 (osanetant) at different doses, compared to placebo, for the treatment of moderate to severe Vasomotor Symptoms (VMS) associated with menopause. The trial is intended to enroll approximately 56 post-menopausal women aged 40-65, who experience moderate to severe hot flashes. Subjects are to receive twice daily doses of either 50 mg,...